The company british biotech Synairgen, based in Southampton, has announced Monday via a press of the "positive results" regarding a treatment it is developing against the disease Covid-19, caused by the coronavirus.
Read also What the current crisis tells us of future crises
the preliminary results of the clinical trial suggest that this new treatment significantly reduces the number of patients requiring intensive care. Thus, the patients to which the treatment was administered were two times more likely to recover from the Covid-19 than those who received the placebo, points out Synairgen.